Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients

Myles A. Ingram¹ | Brianna N. Lauren¹ | Yoanna Pumpalova² | Jiheum Park¹ | Francesca Lim¹ | Susan E. Bates³ | Fay Kastrinos³,⁴ | Gulam A. Manji³ | Chung Yin Kong⁵ | Chin Hur¹,³,⁴

¹Division of General Medicine, Columbia University Irving Medical Cancer and the Vagelos College of Physicians and Surgeons, New York, New York, USA
²Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA
³Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA
⁴Division of Digestive and Liver Diseases, Columbia University Irving Medical Cancer and the Vagelos College of Physicians and Surgeons, New York, New York, USA
⁵Division of General Medicine, Mount Sinai School of Medicine, New York, New York, USA

Correspondence
Chin Hur, Columbia University Irving Medical Center, Department of General Medicine, 622 W 168th St, New York, NY 10032, USA. Email: ch447@cumc.columbia.edu

Funding information
National Institutes of Health, Grant/Award Numbers: R01CA212086, R01CA212086-02

Abstract

Background: The 2020 National Comprehensive Cancer Network guidelines recommend neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine plus nab-paclitaxel (G-nP) for borderline resectable/locally advanced pancreatic ductal adenocarcinoma (BR/LA PDAC).

Aim: The purpose of our study was to compare treatment outcomes, toxicity profiles, costs, and quality-of-life measures between these two treatments to further inform clinical decision-making.

Methods and Results: We developed a decision-analytic mathematical model to compare the total cost and health outcomes of neoadjuvant FOLFIRINOX against G-nP over 12 years. The model inputs were estimated using clinical trial data and published literature. The primary endpoint was incremental cost-effectiveness ratios (ICERs) with a willingness-to-pay threshold of $100,000 per quality-adjusted-life-year (QALY). Secondary endpoints included overall (OS) and progression-free survival (PFS), total cost of care, QALYs, PDAC resection rate, and monthly treatment-related adverse events (TRAЕ) costs (USD). FOLFIRINOX was the cost-effective strategy, with an ICER of $60856.47 per QALY when compared to G-nP. G-nP had an ICER of $44639.71 per QALY when compared to natural history. For clinical outcomes, more patients underwent an “R0” resection with FOLFIRINOX compared to G-nP (84.9 vs. 81.0%), but FOLFIRINOX had higher TRAE costs than G-nP ($10905.19 vs. $4894.11). A one-way sensitivity analysis found that the ICER of FOLFIRINOX exceeded the threshold when TRAE costs were higher or PDAC recurrence rates were lower.

Conclusion: Our modeling analysis suggests that FOLFIRINOX is the cost-effective treatment compared to G-nP for BR/LA PDAC despite having a higher cost of total care due to TRAE costs. Trial data with sufficient follow-up are needed to confirm our findings.

Keywords
chemotherapy, clinical cancer research, pancreatic cancer
Adoption of neoadjuvant chemotherapy for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC) treatment is quickly increasing, and the field is shifting away from adjuvant therapy. Several clinical trials have evaluated the effectiveness of therapies such as FOLFIRINOX and gemcitabine plus nab-paclitaxel (G-nP) for PDAC patients. These regimens have also been used in patients with BR/LA PDAC to downsize tumors to the point where they may be resected. Currently, the 2020 National Comprehensive Cancer Network (NCCN) guidelines recommend either neoadjuvant G-nP or neoadjuvant FOLFIRINOX for patients with BR/LA PDAC.

In a previous study, we compared the effectiveness and cost-effectiveness of neoadjuvant versus adjuvant therapies for BR/LA PDAC. Neoadjuvant FOLFIRINOX was compared to adjuvant gemcitabine and adjuvant gemcitabine plus capecitabine. We found that neoadjuvant FOLFIRINOX was the optimal strategy when compared to the two adjuvant strategies but were not able to incorporate other neoadjuvant therapies due to a lack of data.

To date, the efficacy and cost-effectiveness of neoadjuvant FOLFIRINOX and G-nP in BR/LA PDAC have not been compared in a randomized, prospective clinical trial. Because of this lack of clinical trial data, we developed a decision-analytic model incorporating the best available published data to simulate a hypothetical clinical trial between FOLFIRINOX and G-nP. The aim of this study is to compare these two neoadjuvant strategies in terms of cost-effectiveness for BR/LA PDAC treatment.

2 | METHODS

2.1 | Model overview and target population

We developed a Markov model, using Python 3.7, to follow and track hypothetical cohorts of BR/LA PDAC patients undergoing neoadjuvant therapy prior to resection through a simulated trial (Figure 1). The model cohort consisted of 60-year-old BR/LA PDAC patients who have not previously received treatment (first-line); the model was cycled monthly for 12 years. For this analysis, we assumed a uniform tumor staging and location for each cohort in each strategy in order to have an unbiased comparison between strategies. In terms of tumor staging and location, G-nP patients and FOLFIRINOX patients had similar characteristics (Table S1). The time between diagnosis (beginning of the model) and resection was 6 months. Patients in the FOLFIRINOX arm received 6 cycles on a day 1 and 15 infusion 28-day schedule and patients in the G-nP arm received 6 cycles on a day 1, 8, and 15 infusion 28-day schedule, consistent with clinical trials and published literature. Causes of death in the model included all-cause, cancer, and surgical mortality. After the completion of the chemotherapy cycles, patient in the neoadjuvant treatment state, move into the resection state where they receive resection surgery. After resection, patients were assigned R0/R1 status and entered either a remission stage or a recurrence stage. R0/R1 status was defined as whether patients had microscopic cancer cells present at the margin of the primary tumor after resection. From the remission stage, patients either transitioned to the recurrence stage or died from all causes. From the recurrence stage, patients either died from cancer or all cause. All patients who did not complete neoadjuvant therapy received either palliative care, second-line treatment, or died. Additionally, we factored in both the likelihood that a patient would develop adverse events during neoadjuvant chemotherapy and the probability of resection surgery complications. Patients in the natural history arm received no neoadjuvant treatment or surgery for their BR/LA PDAC.

Furthermore, we included a hypothetical scenario analyses to our model. This scenario explored the base analysis in a center of excellence setting. For this scenario, the dropout rates, PDAC recurrence rates, and R0 rates were adjusted to align with published literature from centers of excellence. We defined a center of excellence as a highly specialized and interdisciplinary program within a healthcare institution that supplies expertise and resources to a particular medical area, in this case PDAC. We included the hypothetical scenario analysis to investigate what effect a center-of-excellence setting had on our model results. The parameters of the scenario can be found in Table S2.

2.2 | Study perspective and outcomes

We assessed the incremental cost-effectiveness of G-nP versus FOLFIRINOX from the perspective of the U.S. healthcare system.
The primary endpoint was the optimal neoadjuvant treatment, defined as the highest QALYs with an incremental cost-effectiveness ratio (ICER) below a willingness-to-pay threshold (WTP) of $100,000 (2021 USD). Secondary endpoints included overall survival (OS), progression-free survival (PFS), total cost of care, R0 status, PDAC resection rate, and monthly treatment-related adverse events (TRAE) costs. Costs and QALYs were discounted at 3% per year, and a half-cycle correction was applied to QALYs and unadjusted life-years.

2.3 Health state transition probabilities, model calibration

We estimated the transition probabilities of our Markov model from published literature and clinical trial data (Tables 1 and 2). We calibrated our model by fitting the overall and progression free survival curves of each arm, including the natural history arm, to published Kaplan–Meier curves.7–11,32 We extracted data from retrospective published data and preliminary clinical trial data to inform our model. In instances where BR/LA PDAC neoadjuvant treatment data was limited, we used conservative estimates from metastatic patient cohorts. We used a software called Engauge Digitizer to extract the data from the overall and progression free survival curves from published literature and used that data to calibrate cancer progression rates of our model. FOLFIRINOX clinical trials were more inclined to have younger patients, lower Charlson Comorbidity Index (CCI) scores, and higher likelihood of patients with N0 status than G-nP clinical trials. Since FOLFIRINOX clinical trials tend to enroll healthier and more robust patients, we used a more conservative estimate of overall survival and progression-free survival in the FOLFIRINOX trials to reconcile the baseline differences that like existed between patients enrolled in FOLFIRINOX and G-nP trials (Table S1). We also validated our model by comparing model outputs such as R0 rate, patient resection rate, and median OS/PFS with published clinical endpoints.6–10,30–42 All-cause mortality was derived from the average of male and female 2016 U.S. life tables.

2.4 Costs and health state utility values

Costs were calculated from a payer perspective and no indirect costs were included in the analysis. The costs of chemotherapy drugs were based on Centers for Medicare and Medicaid (CMS) 2020 average sale price. Capecitabine and radiation therapy costs for the neoadjuvant arms were estimated from published literature.6,30 Costs associated with hospitalization for TRAE were based on Medicare reimbursement rates from the CMS Physician Fee Schedule. Rates of hospitalization due to TRAE were estimated from clinical trial data and published literature. Costs associated with PDAC treatment, palliative care, second-line treatment, drug administration, and resection surgery were derived from Medicare reimbursement rates used in previous cost-effectiveness analyses of neoadjuvant PDAC treatment.12,31–36 Additionally, all utilities and dis-utilities used to calculate QALYs were based on previously published cost-effectiveness analyses.12,13,37–41 All costs were inflation-adjusted to 2021. References for utility and cost estimates can be found in Tables 1 and 2.

### Table 1 General model parameters

| Parameters | Value | Range for sensitivity analysis | Source |
|------------|-------|--------------------------------|--------|
| Age (years) | 60 | 38–66 | 6,7,30,31 |
| 30-day BR/LA PDAC mortality rate | 0.24 | 0.17–0.57 | 6,17,30 |
| 30-day surgical mortality rate | 0.015 | 0.01–0.053 | 6,32 |
| Post-surgical pancreatic fistula rate | 0.093 | 0–0.24 | 6,33,34 |
| Progression-free survival BR/LA PDAC | 0.8 | 0.68–0.88 | 6,23,24,27 |
| Costs | | | |
| PDAC resection surgery cost | $29580.00 | $15000.00–$41000.00 | 6,35 |
| Palliative care cost | $101388.00 | $92820.00–$103020.00 | 6,36 |
| Capecitabine and radiation per month | $1377.00 | $840.00–$1938.00 | 6,15 |
| Chemoradiation hospitalization costs | $2856.00 | $1734.00–$3774.00 | 6,15 |
| Endoscopic Ultrasound | $1570.80 | $0.00–$1570.80 | 6,27 |
| PDAC costs per month (inpatient) | $5508.00 | $3162.00–$7446.00 | 6,22 |
| Utilities | | | |
| Progression-free PDAC utility | 0.80 | 0.68–0.88 | 6,17,23,24,27 |
| Progressive disease | 0.73 | 0.62–0.80 | 6,17,23,24,27 |
| Palliative care | 0.14 | 0–0.34 | 6,23 |
| Recovery from surgery | 0.78 | 0.78–0.81 | 6,27 |

Abbreviations: BR/LA, Borderline resectable/locally advanced; PDAC, pancreatic ductal adenocarcinoma.
### TABLE 2  Strategy specific parameters

|                      | Nab-paclitaxel plus gemcitabine parameters | FOLFIRINOX parameters |
|----------------------|-------------------------------------------|-----------------------|
| **Chemotherapy cycle length (months)** | 6                                         | 6                     |
| **Dropout rate**     | 0.31                                      | 0.35                  |
| **Toxicity rate**    | 0.65                                      | 0.75                  |
| **Complete cycles**  | 6                                         | 6                     |
| **Surgical complication rate** | 0.23                                      | 0.36                  |
| **Post-surgical pancreatic fistula rate** | 0                                         | 0.05                  |
| **R0 rate**          | 0.81                                      | 0.85                  |
| **PDAC recurrence rate** | 0.53                                      | 0.61                  |
| **Hospitalization for toxicity** | 0.25                                      | 0.37                  |
| **Lymph node positivity** | 0.72                                      | 0.56                  |
| **Survival after recurrence (R0 resection) (months)** | 18.7                                      | 21                    |
| **Survival after recurrence (R1 resection) (months)** | 16                                        | 17                    |
| **Survival after recurrence (N0 disease) (months)** | 20                                        | 22                    |
| **Survival after recurrence (N1 disease) (months)** | 16                                        | 18                    |
| **Survival on second-line therapy (months)** | 9                                         | 7−11                  |
| **Costs**            |                                           |                       |
| **First-line chemotherapy cost per cycle** | $8882.41                                  | $863.50               |
| **Toxicity cost per cycle (first-line)** | $918.00                                   | $1734.00              |
| **Second-line chemotherapy cost per month** | $4080.00                                  | $13209.00             |
| **Toxicity cost per month (second-line)** | $2094.75                                  | $6778.80              |
| **Administration cost per month (first-line and second-line)** | $568.98                                   | $578.79               |
| **Utilities**        |                                           |                       |
| **Chemotherapy disutility** | −0.24                                     | −0.12                 |
| **Chemotherapy toxicity disutility** | −0.24                                     | −0.19−0.05            |
2.5  |  Sensitivity analyses

We performed one-way deterministic sensitivity analyses, which involved changing each parameter individually across a plausible range of values, to determine the robustness of our base-case results (Tables 1 and 2). Probabilistic sensitivity analyses were also conducted by changing all input parameters at the same time. We sampled the parameter values on specific distributions and ran 10,000 iterations to investigate how ICER of the optimal strategy was affected.

3  |  RESULTS

3.1  |  Base-case analyses

Neoadjuvant FOLFIRINOX treatment was the optimal strategy in the base-case model with a total cost of $240,877 and 2.99 QALYs. Furthermore, patients in this arm had a resection rate of 67.32%, with 84.90% of those undergoing surgery achieving an R0 resection. Patients in the FOLFIRINOX arm had TRAE costs of $10,905 per month. FOLFIRINOX yielded an ICER of $80,862 compared to neoadjuvant G-nP treatment, which was below the $100,000 WTP threshold. G-nP had a total cost of $205,161, 2.54 QALYs, and an ICER of $49,196 compared to natural history (Figure 2). Patients in the G-nP arm had a resection rate of 59.33%, with 80.99% of patients undergoing surgery achieving an R0 resection (Table S3). The G-nP arm was associated with TRAE costs of $48,94 per month. In terms of survival, FOLFIRINOX had a higher median OS and PFS and higher 10-year OS and PFS compared to G-nP (median OS 34.01 vs. 28.27 months; median PFS 29.54 vs. 24.88; 10-year OS 9.73% vs. 5.24%; 10-year PFS 8.48% vs. 4.38%; Figure S1). The natural history arm had a median OS/PFS of 12.13/7.29 months and no survival after 10 years (Table 3).

3.2  |  Center-of-excellence scenario

In the center-of-excellence scenario, FOLFIRINOX remained the optimal strategy. In this scenario, FOLFIRINOX had an ICER of $73,124, total cost of $251,718, and 3.42 QALYs. The G-nP strategy resulted in an ICER of $45,795, total cost of $217,753, 2.96 QALYs. Both FOLFIRINOX and G-nP had higher median, 5-year, and 10-year OS and PFS in this scenario compared to the base case, but a smaller percentage of the cohort underwent resection compared to the base case scenario (FOLFIRINOX 57.9 vs. 67.32%; G-nP 52.6 vs. 59.33%; Table S4).

3.3  |  Sensitivity analyses

The model outcomes were most sensitive to monthly toxicity cost for treatment, resection surgery cost, PDAC recurrence rate, PDAC survival rate, and rate of TRAEs. Increasing monthly toxicity costs for FOLFIRINOX caused the strategy to exceed the $100,000 WTP threshold, thus making G-nP the optimal strategy. Increasing the rate of TRAEs, the dropout rate, and the PDAC recurrence rate for FOLFIRINOX all resulted in an ICER above the WTP threshold and decreasing the PDAC progression-free survival rate caused G-nP to dominate FOLFIRINOX (Figure S2). For G-nP, the ICER did not exceed the $100,000 WTP threshold for all the plausible ranges of input parameters tested (Figure S3). Additionally, although the model was also sensitive to R0 rate, PDAC mortality rate, second-line treatment cost, and utility associated with progressive disease, changing these parameters within the pre-specified parameter ranges did not alter the model results.

The probabilistic sensitivity analysis results demonstrated that the base-case results were robust to parameter uncertainty. FOLFIRINOX remained the optimal strategy in 76.8% of the
TABLE 3  
| Base-case results |
|------------------|----------------|----------------|----------------|----------------|----------------|-----------------------------|
|                  | Life-years     | Cost (USD)     | QALYs          | Median OS/PFS  | 5-year OS/PFS  | 10-year OS/PFS | TRAE cost per month | R0 resection^ | ICERs |
|------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------------|--------------|-------|
| Natural history  | 1.16           | $112 251       | 0.654          | 13/7.87        | 0.20/0.01%     | 0/0%           | –                    | –            | –     |
| G-nP             | 3.41           | $205 161       | 2.54           | 28.27/24.88    | 21.33/17.92%   | 5.24/4.38%     | $4894               | 80.99%       | $49 196|
| FOLFIRINOX       | 4.07           | $240 877       | 2.99           | 34.01/29.54    | 29.38/25.68%   | 9.73/8.48%     | $10 905             | 84.90%       | $80 862|

^R0 resection % only includes those who made it to surgery.

Our results must be interpreted with study limitations in mind. Due to the scarcity of prospective, randomized clinical trial data for patients with BR/LA PDAC treated with neoadjuvant chemotherapies, model assumptions and inputs relied on preliminary clinical trial data and retrospective published data. Using these data sources may have incorporated bias in our analysis, including referral bias, and/or selection bias of healthier patients compared to the average BR/LA PDAC patient. In instances where BR/LA data was limited, we consistently used the more conservative estimates from metastatic patient cohorts, biasing our results against neoadjuvant FOLFIRINOX or the null. Additionally, FOLFIRINOX trials have a selection bias, often enrolling healthier patients compared to G-nP trials. We attempted to reconcile this selection bias by calibrating to a more conservative estimate of the overall survival and progression-free survival confidence interval in FOLFIRINOX trials so that G-nP and FOLFIRINOX could be compared with minimal bias. When there was limited cost and utility data for the neoadjuvant setting, we used published data from metastatic PDAC cohorts to derive conservative estimations. Lastly, we also assumed uniform comorbidity status across patients assigned to all treatment arms in the model, which is likely an oversimplification of real-life clinical practice. Given high rates of treatment related toxicity, comorbidities and patient performance status play an important role in individualizing a neoadjuvant treatment plan for patients with BR/LA PDAC. Because of these data limitations, we assuaged concerns of uncertainty about our model by verifying our model outputs through rigorous sensitivity analyses and aligning our outcomes with published clinical data.

5  | CONCLUSION

In summary, our analysis found that FOLFIRINOX is the optimal neoadjuvant chemotherapy regimen compared to gemcitabine plus nab-paclitaxel for BR/LA PDAC, despite having a higher cost of total care due to TRAE costs. This comparison of neoadjuvant PDAC chemotherapy strategies gives new insight into the selection of treatment regimens for BR/LA patients. Data from prospective randomized clinical trials with sufficient follow-up are needed to confirm our findings.

ACKNOWLEDGMENT

This work was supported by the National Institutes of Health.
CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
Study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, statistical analysis, technical support, M.A.I.: Study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, statistical analysis, technical support, B.L.; Acquisition of data, analysis and interpretation of data, drafting of the manuscript, Y.P.; Acquisition of data, analysis and interpretation of data, critical revision of manuscript for important intellectual content, J.P.; Acquisition of data, analysis and interpretation of data, critical revision of manuscript for important intellectual content, F.L.; Analysis and interpretation of data, critical revision of the manuscript for important intellectual content, F.K.; Critical revision of the manuscript for important intellectual content, analysis and interpretation of data, G.A.M.; Critical revision of the manuscript for important intellectual content, analysis and interpretation of data, C.Y.K.; Study concept and design, critical revision of the manuscript for important intellectual content, obtained funding, technical and material support, study supervision, C.H.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available under CUMC-HIRE in the PDAC_model repository at https://github.com/CUMC-HIRE/PDAC_model

ETHICAL STATEMENT
This study was approved by the Institutional Review Board at Columbia University Medical Center, New York.

ORCID
Myles A. Ingram https://orcid.org/0000-0001-9703-5805
Brianna N. Lauren https://orcid.org/0000-0003-3608-6777
Chin Hur https://orcid.org/0000-0002-2819-7576

REFERENCES
1. Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114(7):737-743. https://doi.org/10.1038/bjc.2016.45
2. Miyasaka Y, Ohtsuka T, Kimura R, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery. Ann Surg Oncol. 2019;26(5):1528-1534. https://doi.org/10.1245/s10434-019-07309-8
3. Paniccia A, Edil BH, Schlicker RD, et al. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine (Baltimore). 2014;93(27):e198. https://doi.org/10.1097/MD.0000000000000198
4. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiation therapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963-969. https://doi.org/10.1001/jamaoncol.2018.0329
5. National Comprehensive Cancer Network. Pancreatic Cancer 2020. https://www.nccn.org/patients/guidelines/content/PDF/pancreatic-patient.pdf
6. Choi JG, Nipp RD, Tramontano A, et al. Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: results of a decision analysis. Oncologist. 2019;24(7):945-954. https://doi.org/10.1634/theoncologist.2018-0114
7. Dhir M, Zenati MS, Hamad A, et al. FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma. Ann Surg Oncol. 2018;25(7):1896-1903. https://doi.org/10.1245/s10434-018-6512-8
8. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capcitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet. 2017;389(10073):1011-1024. https://doi.org/10.1016/S0140-6736(16)32409-6
9. Conroy T, Hammel P, Hebbard M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-2406. https://doi.org/10.1056/NEJMoa1809775
10. Ielpo B, Canuso R, Duran H, et al. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Surg Oncol. 2017;26(4):402-410. https://doi.org/10.1016/j.suronc.2017.08.003
11. Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413-423. https://doi.org/10.1016/s2546-1253(18)30081-5
12. Attard CL, Brown S, Allou K, Moore MJ. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol Tor Ont. 2014;21(1):e41-e51. https://doi.org/10.3747/co.c21.1327
13. Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol Tor Ont. 2013;20(2):e90-e106. https://doi.org/10.3747/co.20.1223
14. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12-17. https://doi.org/10.1097/SLA.0000000000000867
15. Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199. https://doi.org/10.1186/1471-2407-12-199
16. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. https://doi.org/10.1371/journal.pmed.1000267
17. Alexakis N, Sutton R, Neoptolemos JP. Surgical treatment of pancreatic fistula. Dig Surg. 2004;21(4):262-274. https://doi.org/10.1159/000080199
18. Bassi C, Butturini G, Molinari E, et al. Pancreatic fistula rate after pancreatic resection. The importance of definitions. Dig Surg. 2004;21(1):54-59. https://doi.org/10.1159/000075943
19. Holbrook RF, Hargrave K, Traverso LW. A prospective cost analysis of pancreaticoduodenectomy. Ann J Surg. 1996;171(5):508-511. https://doi.org/10.1016/s0002-9610(96)00016-5
20. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001;19(5):1266-1274. https://doi.org/10.1200/JCO.2001.19.5.1266
21. Michelakos T, Pergolini I, Castillo CF, et al. Predictors of Resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269(4):733-740. doi:10.1097/SLA.0000000000002600

22. Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153-1159. doi:10.1245/s10434-014-4225-1

23. Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreatic cancer: a new treatment paradigm? Oncologist. 2014;19(3):266-274. https://doi.org/10.1634/theoncologist.2013-0273

24. Nipp RD, Zanconato A, Zheng H, et al. Predictors of early mortality after surgical resection of pancreatic adenocarcinoma in the era of neoadjuvant treatment. Pancreas. 2017;46(2):183-189. https://doi.org/10.1097/MPA.0000000000000731

25. Sadot E, Doussot A, O'Reilly EM, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512-3521. doi:10.1245/s10434-015-4647-4

26. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999;130(10):789-799. https://doi.org/10.7326/0003-4819-130-10-199905180-00002

27. Eldor J, Fortenberry JL. Centers of excellence in healthcare institutions: what are they and how to assemble them. BMC Health Serv Res. 2017;17(1):425. https://doi.org/10.1186/s12913-017-2340-y

28. Faris JE, Blaszkowski LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital cancer center experience. Oncologist. 2013;18(5):543-548. https://doi.org/10.1634/theoncologist.2012-0435

29. Sherman WH, Chu K, Chabot J, et al. Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma: Unresectable locally advanced pancreatic cancer. Cancer. 2015;121(5):673-680. https://doi.org/10.1002/cncr.29112

30. Cerullo M, Gani F, Chen SY, et al. Assessing the financial burden associated with treatment options for resectable pancreatic cancer. Ann Surg. 2018;267(3):544-551. https://doi.org/10.1097/SLA.0000000000002069

31. Kim SS, Nakakura EC, Wang ZJ, et al. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016;114(5):587-596. https://doi.org/10.1002/jso.24375

32. Bilir SP, Ma Q, Zhao Z, Wehler E, Munakata J, Barber B. Economic burden of toxicities associated with treating metastatic melanoma in the United States. Am Health Drug Benefits. 2016;9(4):203-213.

33. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916-1924. https://doi.org/10.1002/cncr.20983

34. Goldstein DA, Krishna K, Flowers CR, El-Rayes BF, Bekaii-Saab T, Noonan AM. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Med Oncol Northwood Lond Engl. 2016;33(5):48. https://doi.org/10.1007/s12032-016-0762-8

35. Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(10):1112-1118. https://doi.org/10.1200/JCO.2014.58.4904

36. O'Neill CB, Atoria CL, O'Reilly EM, LaFemina J, Henman MC, Elkin EB. Costs and trends in pancreatic cancer treatment. Cancer. 2012;118(20):5132-5139. https://doi.org/10.1002/cncr.27490

37. Aballéa S, Chancellor JVM, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082-1089. https://doi.org/10.1002/cncr.225152

38. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683-690. https://doi.org/10.1038/sj.bjc.6603326

39. Lazzaro C, Barone C, Caprioni F, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):435-446. https://doi.org/10.1080/14737167.2018.1464394

40. Leung HWC, Chan ALF, Muo C-H. Cost-effectiveness of gemcitabine plus modern radiotherapy in locally advanced pancreatic cancer. Clin Ther. 2016;38(5):1174-1183. https://doi.org/10.1016/j.clinthera.2016.03.005

41. Huang JJ, Yeo CJ, Sohn TA, et al. Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg. 2000;231(6):890-898. https://doi.org/10.1097/00000658-20000600-00014

42. Griffin JJ, Poruk KE, Wolfgang CL. Pancreatic cancer surgery: past, present, and future. Chin J Cancer Res. 2015;27(4):332-348. https://doi.org/10.3978/j.issn.1000-9604.2015.06.07

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Ingram MA, Lauren BN, Pumpalova Y, et al. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports. 2022;5(9):e1565. doi:10.1002/cnr2.1565